Shin Nippon Biomedical Laboratories, Ltd. (SBLOF)

OTCMKTS · Delayed Price · Currency is USD

7.00

-2.16 (-23.59%)

At close: Jun 9, 2026

-25.21% (1Y)

Market Cap	389.57M -3.9%
Revenue (ttm)	208.66M +1.7%
Net Income	33.04M +6.1%
EPS	0.79 +6.1%
Shares Out	n/a
PE Ratio	11.79
Forward PE	n/a
Dividend	0.19 (2.06%)
Ex-Dividend Date	Sep 29, 2026

Volume	4,000
Open	7.00
Previous Close	9.16
Day's Range	7.00 - 7.00
52-Week Range	7.00 - 12.57
Beta	-0.23
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 5, 2026

About SBLOF

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the pharmaceutical development, transactional research, and medipolis businesses in Japan and internationally. It offers non-clinical testing and non-clinical regulatory consulting for the development of pharmaceuticals, medical devices, or regenerative medicine products, including safety and pharmacology testing, and pharmacokinetic studies. The company also engages in licensing activities for proprietary products which utilize unique intranasal formulation... [Read more]

Industry Diagnostics & Research

Sector Healthcare

Founded 1957

Employees 1,680

Stock Exchange OTCMKTS

Ticker Symbol SBLOF

Financial Performance

In fiscal year 2026, SBLOF's revenue was 32.52 billion, an increase of 0.34% compared to the previous year's 32.41 billion. Earnings were 4.57 billion, a decrease of -7.27%.

Financial numbers in JPY Financial Statements